Singapore’s National Precision Medicine Strategy: Supporting Data-driven Healthcare
Presented by SGInnovate and Precision Health Research Singapore (PRECISE)
Partnered with CATALYST
Like many other countries, Singapore faces evolving healthcare demands, driven by a rapidly ageing population and increased prevalence of chronic diseases. Precision Medicine (PM) is an innovative approach. Scientists and doctors consider the patient’s genetic background, lifestyle, and environmental factors to pre-empt the development of diseases and optimise treatments. The National Precision Medicine (NPM) programme is a whole-of-government approach to explore how PM should be best deployed in Singapore to drive research insights, clinical innovation, and economic growth. Through NPM, we hope to contribute to Singaporeans living healthier lives and its eventual impact across other Asian countries.
Join Prof Patrick Tan, Executive Director of Precision Health Research Singapore (PRECISE), to understand more about Singapore’s National Precision Medicine strategy. Prof Tan will also share how Singapore’s SG10K_Health cohort study pioneered the world’s most extensive multi-ethnic genomic databank. He will also talk about the importance of a data-driven medical approach that can help unravel the secrets to more excellent health and disease prevention, paving the way for the future of medicine.
Date: 19 May 2021, Wednesday
Time: 11:00am - 12:00pm (Singapore Time / UTC +8)
11:00am - 11:05am: Welcome and Introduction by SGInnovate
11:05am - 12:00pm: Presentation and Q&A on Singapore’s National Precision Medicine Strategy – Supporting Data-driven Healthcare by Prof Patrick Tan, Executive Director, Precision Health Research Singapore (PRECISE)
Prof Patrick Tan, Executive Director, Precision Health Research Singapore (PRECISE)
Prof Patrick Tan is the Executive Director of Precision Health Research Singapore (PRECISE). As Executive Director of PRECISE, Prof Tan will oversee the implementation of Phase II of Singapore’s Precision Medicine Strategy, which aims to transform healthcare in Singapore and improve patient outcomes through new insights into the Asian genome and data-driven healthcare solutions.
Prof Tan is also Executive Director of the Genome Institute of Singapore and Professor at the Duke-NUS Medical School. He received his BA (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he also received the Charles Yan of sky prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. Other awards include the President’s Scholarship, Loke Cheng Kim scholarship, Young Scientist Award (A-STAR), Singapore Youth Award, Chen New Investigator Award (Human Genome Organisation), President’s Science Award, Japanese Cancer Association International Award, and American Association for Cancer Research Team Science Award (Team Leader). He is a member of the American Society for Clinical Investigation (ASCI) and on the Board of Reviewing Editors for Science magazine.